STORY AT-A-GLANCE
- Drug development for Alzheimer’s has so far been a dismal failure, with 300 failed trials to date
- In a study of the experimental Alzheimer’s drugs gantenerumab and solanezumab, they failed to slow cognitive decline after an average of five years
- The drugs were intended to remove beta-amyloid from the brain, but beta-amyloid is a symptom of Alzheimer’s — not the cause
- Bredesen’s ReCODE protocol evaluates 150 factors, including biochemistry, genetics and historical imaging, known to contribute to Alzheimer’s disease
- Bredesen has published a case report of 100 patients using the ReCODE protocol, in which all show sustained improvement in symptoms